Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 7
Opinion
Video
Highlighting the Available CDK4/6 Inhibitors
Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.
Video Player is loading.
Related Videos
Leveraging Technology to Enhance Women’s Health and Access to Care
Staying Current Regarding Available Therapeutic Options and Updates to Treatment Guidelines
Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows
Monitoring Strategies for Managing ADC Toxicities in mBC
Examining the 505(b)(2) Pathway and Implementation into EHR
Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies
Strategies for Supporting Adherence to Treatment and Evaluating Efficacy
Patient Education When Initiating Treatment for Menopausal Symptoms
Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care
Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies
Related Content
